ロード中...
Current Status of Biosimilar Growth Hormone
As the first wave of biopharmaceuticals is set to expire, biosimilars or follow-on protein products (FOPPs) have emerged. The regulatory foundation for these products is more advanced and better codified in Europe than in the US. Recent approval of biosimilar Somatropin (growth hormone) in Europe an...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Hindawi Publishing Corporation
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2777019/ https://ncbi.nlm.nih.gov/pubmed/19956705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2009/370329 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|